期刊文献+

新木桶原理视域下的肿瘤学学科建设探讨 被引量:1

Construction of oncology discipline in the perspective of new barrel theory
下载PDF
导出
摘要 传统的木桶原理揭示了当前最为严重的问题,而新木桶原理则重视木桶的整体性、一致性和完整性,强调管理中的团队建设和协同创新发展,反映管理组织机构既扬长又攻短,多方协作集成发展的特色。运用新木桶原理,不仅有助于深化肿瘤学发展改革、提高肿瘤学学科整体水平,也是提升高等医学教育质量的必然选择。 Traditional barrel principle reveals what the most serious problem is,and the principle of new barrel attaches great importance to its entirety,consistency and integrity,emphasizes team building and collaborative innovation development,reflects the characteristics of the management organization which stresses collaborative development with both its strengths and weaknesses. Application of new barrel principle not only helps to deepen oncology reform development and raise the overall level of oncology discipline,but is an inevitable choice to improve higher medical education quality as well.
作者 邵红芳
出处 《基础医学教育》 2016年第4期334-336,共3页 Basic Medical Education
基金 山西省软科学研究项目资助(2013041082-02) 山西医科大学博士启动基金资助项目(03201313)
关键词 肿瘤学 学科建设 新木桶原理 oncology discipline construction new barrel theory
  • 相关文献

参考文献6

二级参考文献61

  • 1许良中.肿瘤病理研究的历史回顾与展望[J].中华肿瘤杂志,2004,26(8):509-512. 被引量:2
  • 2张惠荣,姜玉梅.SCI与MEDLINE收录肿瘤学期刊的比较[J].中华医学图书情报杂志,2005,14(1):62-62. 被引量:3
  • 3姜斌,朱冠山,刘峰,龚圣济,姚宝娣,钟镭,朱忠政,曾骥孟.中国人非小细胞肺癌EGFR基因突变的研究[J].上海第二医科大学学报,2005,25(11):1148-1150. 被引量:13
  • 4Salomon D S, Brandt T, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies[J]. Crit Rev Oneol Hematol, 1995, 19(3) : 183.
  • 5Fukuoka M, Yano S, Giaceone G, et al. Multi- institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non - small - cell lung cancer[J]. J Clin Oncol, 2003, 21: 2237.
  • 6Kris M G, Natale R B, Herbst R S, et al. Efficacy of gefi-tinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non - small cell lung cancer[J]. JAMA, 2003, 290: 2149.
  • 7Thatcher N, Chang A, Parikh P, et al. ISEL: A phase Ⅲ Ⅲ survival study comparing gefltinib (lressa) plus best supportive care (BSC) with placebo plus BSC in patients with advanced non small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens [ J ]. Proceedings from the 11th World Conference on Lung Cancer, Barcelona, Spain. 2005, Abstract # Pr4.
  • 8Lynch T J, Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350: 2129.
  • 9Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin- paelitaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009, 361(10): 947.
  • 10Zhou C C, Wu Y L, Chen G, et al. Updated efficacy and quality- of - life (QoL) analyses in OPTIMAL, a phase m, randomized, open-label study of first - line erlotinib versus gemeitabine/carboplatin in patients with EGFR- activating mutation - positive ( EGFR Act Mut + ) advanced non-small cell lung cancer (NSCLC)[ J ]. J Clin Oncol, 2011, 29(suppl) : abstr7520.

共引文献64

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部